Granulocyte-colony stimulating factor decreases the extent of ovarian damage caused by cisplatin in an experimental rat model

J Gynecol Oncol. 2014 Oct;25(4):328-33. doi: 10.3802/jgo.2014.25.4.328. Epub 2014 Jun 18.

Abstract

Objective: To investigate whether granulocyte-colony stimulating factor (G-CSF) can decrease the extent of ovarian follicle loss caused by cisplatin treatment.

Methods: Twenty-one adult female Sprague-Dawley rats were used. Fourteen rats were administered 2 mg/kg/day cisplatin by intraperitoneal injection twice per week for five weeks (total of 20 mg/kg). Half of the rats (n=7) were treated with 1 mL/kg/day physiological saline, and the other half (n=7) were treated with 100 μg/kg/day G-CSF. The remaining rats (n=7, control group) received no therapy. The animals were then euthanized, and both ovaries were obtained from all animals, fixed in 10% formalin, and stored at 4°C for paraffin sectioning. Blood samples were collected by cardiac puncture and stored at -30°C for hormone assays.

Results: All follicle counts (primordial, primary, secondary, and tertiary) and serum anti-Müllerian hormone levels were significantly increased in the cisplatin+G-CSF group compared to the cisplatin+physiological saline group.

Conclusion: G-CSF was beneficial in decreasing the severity of follicle loss in an experimental rat model of cisplatin chemotherapy.

Keywords: Anti-Müllerian hormone; Cisplatin; Granulocyte-colony stimulating factor; Ovarian follicle; Ovary.

MeSH terms

  • Animals
  • Anti-Mullerian Hormone / blood
  • Antineoplastic Agents / toxicity*
  • Biomarkers / blood
  • Cisplatin / toxicity*
  • Disease Models, Animal
  • Drug Evaluation, Preclinical / methods
  • Female
  • Fertility Preservation / methods
  • Granulocyte Colony-Stimulating Factor / therapeutic use*
  • Ovarian Follicle / drug effects
  • Ovarian Follicle / pathology
  • Primary Ovarian Insufficiency / blood
  • Primary Ovarian Insufficiency / chemically induced
  • Primary Ovarian Insufficiency / pathology
  • Primary Ovarian Insufficiency / prevention & control*
  • Rats, Sprague-Dawley

Substances

  • Antineoplastic Agents
  • Biomarkers
  • Granulocyte Colony-Stimulating Factor
  • Anti-Mullerian Hormone
  • Cisplatin